Beyond prognostic value, our study also sheds light on potential therapeutic vulnerabilities, particularly focusing on PAX3. Among the four ERGs, PAX3 showed the strongest correlation with the risk score and was consistently overexpressed in glioma tissues across datasets. This evidence concerns the gene PAX3 and central nervous system cancer.